ABSTRACT
The Prostate Imaging Reporting and Data System (PI-RADS) has good ability to identify the nature of lesions on prostate magnetic resonance imaging (MRI). However, some lesions are still reported as PI-RADS 4 and 5 but are biopsy-proven benign. Herein, we aimed to summarize the reasons for the negative prostate biopsy of patients who were assessed as PI-RADS 4 and 5 by biparameter MRI. We retrospectively sorted out the prostate MRI, treatment, and follow-up results of patients who underwent a biparameter MRI examination of the prostate in The First Affiliated Hospital of Nanjing Medical University (Nanjing, China) from August 2019 to June 2021 with PI-RADS 4 and 5 but a negative biopsy. We focused on reviewing the MRI characteristics. A total of 467 patients underwent transperineal prostate biopsy. Among them, biopsy pathology of 93 cases were negative. After follow-up, 90 patients were ruled out of prostate cancer. Among the 90 cases, 40 were considered to be overestimated PI-RADS after review. A total of 22 cases were transition zone (TZ) lesions with regular appearance and clear boundaries, and 3 cases were symmetrical lesions. Among 15 cases, the TZ nodules penetrated the peripheral zone (PZ) and were mistaken for the origin of PZ. A total of 17 cases of lesions were difficult to distinguish from prostate cancer. Among them, 5 cases were granulomatous inflammation (1 case of prostate tuberculosis). A total of 33 cases were ambiguous lesions, whose performance was between PI-RADS 3 and 4. In summary, the reasons for "false-positive MRI diagnosis" included PI-RADS overestimation, ambiguous images giving higher PI-RADS, diseases that were really difficult to distinguish, and missed lesion in the initial biopsy; and the first two accounted for the most.
Subject(s)
Male , Humans , Prostatic Neoplasms/pathology , Magnetic Resonance Imaging/methods , Retrospective Studies , Image-Guided Biopsy/methods , Prostate/pathologyABSTRACT
Objective To compare the diagnostic performance of PI-RADS v2.1 and PI-RADS v2 in the detection of clinically significant prostate cancer(csPCa) by Meta-analysis. Methods The major biomedical databases were searched (CNKI, CBM, Medline, and Embase) with the keywords "PIRADS v2.1" or "PI-RADS v2.1". The Quality Assessment of Diagnostic Accuracy Studies Tool v2 (QUADAS-2) was used to evaluate literature quality. Meta-analysis was performed using STATA17.0 and ReMan5.4 software. Forest plots were used to represent the sensitivity and specificity of PI-RADS v2.1 and PI-RADS v2 for each study. Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were combined, and diagnostic performance was evaluated using asummary receiver operating characteristic curve (SROC). Subgroup analysis was performed on three covariables: tumor location, threshold, and the nationality of authors. Results A total of 12 studies were included, involving 3 158 patients and 3 243 lesions. Forall zones and the whole gland, PI-RADS v2.1 had a larger area under the SROC curve (AUC) for csPCa performance, compared with PI-RADS v2. Subgroup analysis: PI-RADS v2.1 also had a larger area under the SROC (AUC) to detect transitional zone csPCa. Different diagnostic thresholds: when a score of 4 was used for the threshold, PI-RADS v2.1 had the maximum area under SROC (AUC) for csPCa performance detection. Author nationality: Researches of PI-RADS v2.1 in Chinese authors had the largest area under the SROC (AUC) in detecting csPCa performance. Conclusion Compared with PI-RADS v2, the diagnostic performance of PI-RADS v2.1 in detecting csPCa is not obviously improved and overall specificity is still low.
ABSTRACT
Objetivo Evaluar la variabilidad interobservador en el uso de la versión 2.0 del PI- RADS (PI-RADS v2), en lectores experimentados y no experimentados. Materiales y Métodos Estudio retrospectivo de análisis de concordancia de lectores. Entre enero de 2015 y diciembre de 2016, 1.656 sujetos fueron estudiados mediante resonancia magnética multiparamétrica (RMmp) de próstata en nuestra institución. Se estimó la distribución porcentual del reporte en categoría PI-RADS v2, y con esa información, se realizó una selección de 150 casos con esquema de aleatorización estratificada a las distribuciones porcentuales de cada categoría. Dichos casos fueron anonimizados, presentados a tres lectores con cinco, cuatro y dos años de experiencia en lectura de RMmp además de tener más de un año de experiencia en el uso del PI- RADS v2 siendo leídos en forma individual. Los datos resultantes fueron analizados en forma independiente por un cuarto investigador. Resultados El valor de kappa ponderado para los observadores fue de 0,69 (IC 95: 0,64 a 0,75). La mayor concordancia correspondió a los lectores de mayor experiencia, donde alcanza un valor de 0,72 (IC 95%: 0,69 a 0,76). La concordancia entre los valores PI-RADS que determinan seguimiento o bien una intervención de acuerdo a elementos clínicos (1-2-3) y conducta activa (4-5) correspondió a 0,70 (IC 95%: 0,59 a 0,78). Discusión Se logró demostrar un acuerdo sustancial entre radiólogos utilizando el PI- RADS v2 para la detección en RMmp de lesiones sospechosas, mayor entre los dos lectores más experimentados. Sin embargo, la comparación del lector de menor experiencia con los de mayor experiencia también presentó una importante concordancia. Los valores de concordancia entre observadores para PI-RADS 2:4 fueron similares a los reportados en la literatura. Conclusiones El PI-RADSv2 ha demostrado en nuestro centro, con radiólogos dedicados a imágenes de abdomen y estudios de próstata, un alto nivel de acuerdo en la interpretación de la RMmp de próstata, encontrándose a tono con lo reportado en la literatura.
Purpose To evaluate the interobserver variability in the use of the PI-RADS 2.0 version, in experienced and non-experienced readers. Material and Methods Retrospective studyof readers' concordance analysis. Between January 2015 and December 2016, 1656 subjects were studied through multiparametric MRI (RMmp) of prostate in our institution. The percentage distribution of the report was estimated in each PI-RADS category, and a selection of 150 cases with a stratified randomization scheme was made to the percentage distributions of every category. These cases were anonymized, presented to three readers with 5, 4 and 2 years' experience in reading RMmp, and more than one-year experience with PI-RADS v2, and were read individually. The resulting data were analyzed independently by a fourth investigator. Results The weighted kappa value for the observers was 0.69 (IC 95: 0.64 to 0.75). The highest agreement corresponded to the two most experienced readers, where it reached a value of 0.72 (95% CI: 0.69 to 0.76). The concordance between the PI-RADS values that determine follow-up (1-2-3) and active behavior (4-5) corresponded to 0.70 (95% CI: 0.59 to 0.78). Discussion It was possible to demonstrate a substantial agreement between radiologists using the PI-RADS v2 for the detection in RMmp of suspicious lesions, greater among the two most experienced readers. However, the comparison of the less experienced reader with those of greater experience also presented an important concordance. The inter-observer concordance values for PI-RADS 2:4 were like those reported in the literature. Conclusions The PI-RADS v2 has demonstrated, in our center, with radiologists dedicated to abdominal images and prostate studies, a high level of agreement in the interpretation of prostate MRmp.
ABSTRACT
OBJECTIVE@#MRI-Ultrasound fusion guided targeted biopsy has revolutionized the diagnosis of prostatecancer through accurate identification, localization and characterization of prostatic lesions utilizingthe prostate imaging reporting and data system (PI-RADS) scoring system by multiparametric MRI(MPMRI). The fusion prostate biopsy system on the other hand, enables accurate targeting and easyaccess of the tumor. The study objective is to determine the detection rate of clinically-significantprostate cancer using fusion biopsy, and to establish the correlation between PI-RADS score andGleason's score.@*PATIENTS AND METHODS@#A retrospective cohort study was conducted to determine the correlation betweenPI-RADS score and the presence of prostate cancer using MRI-Ultrasound fusion guided transperinealprostate biopsy. This was carried out from June 2017 to July 2018 in a single institution. One hundredthirty five (135) men were included in this study. They presented with an elevated PSA, abnormalDRE or a previous negative prostate biopsy, but with a persistent rise in PSA. A total of 220 prostatelesions were identified. The following characteristics were measured: patient age; the size, location,the PI-RADS score of each lesion, the maximum PI-RADS score for select patients; and the Gleasonscore of discovered tumors.@*RESULTS@# Two hundred twenty PI-RADS 3, 4 and 5 lesions were detected in 135 patients by MPMRI.131 of the 220 lesions were scored as PI-RADS 3, 61 as PI-RADS 4 and 28 as PI-RADS 5. Theselesions were biopsied using the MRI-Ultrasound fusion guided transperineal prostate biopsy system.Thirty-three out of the 131 PI-RADS 3 lesions (25.2%), 44 out of the 61 PI-RADS 4 lesions (72.1%)and 24 out of the 28 PI-RADS 5 lesions (85.7%) respectively were positive for malignancy. Overall,there were 101 (45.9%) lesions classified as PI-RADS 3 to 5 that were positive for prostate carcinoma.Seventy four (74) of the 135 patients (54.8%) were diagnosed with prostate adenocarcinoma. Nineteenout of 65 patients with a maximum score of PI-RADS 3 (29.2%), 33 of 44 with a maximum of PI-RADS 4 (75%) and 22 of 26 with a maximum of PI-RADS 5 (84.6%) harbored malignancy. In termsof location, 45 of the 101 (44.6%) malignancies were in the peripheral sector, 31 (30.7%) in theanterior sector, and 25 (24.8%) in the central sector of the prostate. The mean Gleason grade of PI-RADS 3, 4 and 5 lesions were 6.61, 7.73, and 7.38, respectively. Using Spearman correlation, the rhocoefficient was 0.3153 (p-value =.00013) which denotes a significant positive relationship betweenGleason and PI-RADS score.@*CONCLUSION@#This is the first comprehensive Philippine study on Multiparametric MRI-Ultrasoundfusion-guided transperineal prostate biopsy. Present data validate the superiority of MPMRI in theidentification, localization and characterization of prostate cancers. The authors also verified thepositive correlation between PI-RADS score and Gleason score. Finally, they demonstrated theaccuracy of the MRI- ultrasound fusion-guided transperineal prostate biopsy system in targetingprostate lesions.
ABSTRACT
Objective@#To evaluate the value of Prostate Imaging Reporting and Data System Version 2 (PI-RADS ) based biparametric magnetic resonance imaging (bpMRI) for predicting prostate biopsy results in patients with elevated prostate specific antigen (PSA).@*Methods@#The bpMRI from 539 patients who took transperineal template saturate biopsy from January 2015 to October 2017 were assessed retrospectively. The average age was 69.5 years old (44-88 years), with tPSA level of 7.23 ng/ml (4-10 ng/ml), f/t PSA of 0.183( 0.016-0.504), PSAD of 0.126 ng/ml2 ( 0.025-0.534 ng/ml2) , PV of 72.42 ml ( 18.71-199.51 ml). The age, PSA level, free/total PSA ratio, PSA density, prostate volume, and PI-RADS score of enrolled patients were analyzed for univariate analysis and their difference was compared by chi-square test, t-test. The multivariate logistic regression analysis was also performed through SPSS to select the independent risk factors for prostate cancer (PCa) and clinically significant cancer (csPCa). The receiver operating characteristic curves were also constructed to analyze the sensitivity and specificity of PI-RADS in PCa to explore the best cut-off value for the diagnosis of PCa and csPCa.@*Results@#A total of 539 patients were included in our study with 244 cases being positive and 295 cases being negative. In patients with positive results, 59 patients were diagnosed csPCa. According to univariate analysis results, the age(P<0.001) and PI-RADS score (P<0.001) of the positive patients were higher than the negative patients, and the difference was statistically significant. The age of the csPCa patients (P=0.023), PSAD (P=0.048) and PI-RADS scores (P<0.001) were higher than those of InsPCa patients, and f/t PSA (P=0.027) was lower than that of InsPCa patients with statistically significance. Multivariate logistic regression analysis demonstrated that f /t PSA (OR=2.283, P=0.049) and PI-RADS score (OR=9.046, P<0.001) were independent risk factors for positive biopsy results, while PSAD (OR=4.54, P=0.038) and PI-RADS score (OR=8.254, P<0.001) were independent risk factor for csPCa. The Yoden index analysis of different thresholds for prostate cancer detection indicated that PI-RADS 3 was the optimal threshold for the diagnosis of PCa, and PI-RADS 4 was the optimal threshold for the diagnosis of csPCa. Based on the combination of the above factors, the positive rate of prostate cancer was relatively high in patients with PI-RADS score ≥3 and f/t PSA<0.2 , which accounted for 86.6%(181/209). In contrast, the positive rate in patients with a PI-RADS score of ≤2 and f/t PSA≥0.2 was low, which accounted for 10.7%(6/56). The positive rate of csPCa was relatively high in patients with PI-RADS score≥4 and PSAD≥0.15 ng/ml2, which accounted for 76.0%(38/50). The positive rate of csPCa detected in patients with ≤3 and PSAD<0.15 ng/ml2 was low, which accounted for 0(0/359).@*Conclusions@#PI-RADS score could be used to reduce the unnecessary prostate biopsies in patients with elevated PSA when combined with other PSA related markers. Patients with a PI-RADS score of ≤3 and a PSAD ratio <0.15 ng/ml2 could avoid unnecessary biopsies.
ABSTRACT
Objective@#Assist in clinical decision making by building models to predict the probability of clinically significant prostate cancer (CSPCa) with prostate imaging reporting and data system version 2 (PI-RADs v2) 3 and avoid unnecessary biopsy.@*Methods@#It’s a retrospective study which maintained database of 218 consecutive men who received prostate biopsy and with PI-RADs v2 category 3 in Capital Medical University, Beijing Friendship Hospital between January 2012 to July 2018, the average age was 70.7 years, and the age range was 63-77 years. Among them, 137 patients with benign diseases, 30 patients with clinically insignificant prostate cancer (CIPCa), and 51 patients with CSPCa. Models were established based on clinical variables. The measurement data were expressed as the median (interquartile range) [M(P25, P75)], and the rank sum test was used for comparison between groups; the Chi-square test was used for comparison between the count data groups. The decision curve was used to determine the clinical net benefit unilateral factors generated by the application of the model, univariate and multivariate logistic regression analysis to determine the predictors of positive outcomes. The diagnostic performance of the predictive model was evaluated by the area under the curve (AUC) of receiver operating curve, which was used to assess the overestimation or underestimation of the model, and the decision curve was used to determine the clinical net gain from the application of the model.@*Results@#Detection of prostate caner (PCa) and CSPCa in the PI-RADs v2 cohort were 37.2% (81/218) and 23.4% (51/218). The median prostate specific antigen of CSPCa patients was 12.1 ng/ml, which was higher than CIPCa (9.5 ng/ml) and benign (10.5 ng/ml) patients. The median prostate volume of CSPCa patients was 41.2 ml, lower than CIPCa (45.8 ml) and benign (57.3 ml) patients. The median prostate special antigen density (PSAD) was 0.28 ng/ml2, higher than CIPCa (0.20 ng/ml2) and benign (0.15 ng/ml2) patients. The predictive power of the developed model, based on age, PSAD, lesion region and ADC value, showed a higher AUC than that of parameters alone. Internally validated calibration curves showed that the nomogram might overestimate the risk of PCa when the threshold was above 35%. As for CSPCa, the predicted risk was closer to actual probability when the threshold was above 60%. Decision curves showed that a better net benefit was met when the model was used to guide clinical practice.@*Conclusions@#The models based on age, PSAD, lesion region and ADC value showed internally validated high predictive value for both PCa and CSPCa. It could be used to improve the detection rate of CSPCa and avoid unnecessary biopsy.
ABSTRACT
Objective To evaluate the value of Prostate Imaging Reporting and Data System Version 2 (PI-RADS) based biparametric magnetic resonance imaging (bpMRI) for predicting prostate biopsy results in patients with elevated prostate specific antigen (PSA).Methods The bpMRI from 539 patients who took transperineal template saturate biopsy from January 2015 to October 2017 were assessed retrospectively.The average age was 69.5 years old (44-88 years),with tPSA level of 7.23 ng/ml (4-10 ng/ml),f/t PSA of 0.183(0.016-0.504),PSAD of 0.126 ng/ml2 (0.025-0.534 ng/ml2),PV of 72.42 ml (18.71-199.51 ml).The age,PSA level,free/total PSA ratio,PSA density,prostate volume,and PI-RADS score of enrolled patients were analyzed for univariate analysis and their difference was compared by chi-square test,t-test.The multivariate logistic regression analysis was also performed through SPSS to select the independent risk factors for prostate cancer (PCa) and clinically significant cancer (csPCa).The receiver operating characteristic curves were also constructed to analyze the sensitivity and specificity of PI-RADS in PCa to explore the best cut-off value for the diagnosis of PCa and csPCa.Results A total of 539 patients were included in our study with 244 cases being positive and 295 cases being negative.In patients with positive results,59 patients were diagnosed csPCa.According to univariate analysis results,the age(P ＜ O.001) and PI-RADS score (P ＜ 0.001) of the positive patients were higher than the negative patients,and the difference was statistically significant.The age of the csPCa patients (P =0.023),PSAD (P =0.048) and PI-RADS scores (P ＜ 0.001) were higher than those of InsPCa patients,and f/t PSA (P =0.027) was lower than that of InsPCa patients with statistically significance.Multivariate logistic regression analysis demonstrated that f/t PSA (OR =2.283,P =0.049) and PI-RADS score (OR =9.046,P ＜ 0.001) were independent risk factors for positive biopsy results,while PSAD (OR =4.54,P =0.038) and PI-RADS score (OR =8.254,P ＜ 0.001) were independent risk factor for csPCa.The Yoden index analysis of different thresholds for prostate cancer detection indicated that PI-RADS 3 was the optimal threshold for the diagnosis of PCa,and PI-RADS 4 was the optimal threshold for the diagnosis of csPCa.Based on the combination of the above factors,the positive rate of prostate cancer was relatively high in patients with PI-RADS score ≥3 and t/t PSA ＜ 0.2,which accounted for 86.6％ (181/209).In contrast,the positive rate in patients with a PI-RADS score of ≤2 and f/t PSA≥0.2 was low,which accounted for 10.7％ (6/56).The positive rate of csPCa was relatively high in patients with PI-RADS score≥4 and PSAD≥0.15 ng/ml2,which accounted for 76.0％ (38/50).The positive rate of csPCa detected in patients with ≤ 3 and PSAD ＜ 0.15 ng/ml2 was low,which accounted for 0 (0/359).Conclusions PI-RADS score could be used to reduce the unnecessary prostate biopsies in patients with elevated PSA when combined with other PSA related markers.Patients with a PI-RADS score of ≤ 3 and a PSAD ratio ＜0.15 ng/ml2 could avoid unnecessary biopsies.
ABSTRACT
Objective Assist in clinical decision making by building models to predict the probability of clinically significant prostate cancer (CSPCa) with prostate imaging reporting and data system version 2 (PI-RADs v2) 3and avoid unnecessary biopsy.Methods It's a retrospective study which maintained database of 218 consecutive men who received prostate biopsy and with PI-RADs v2 category 3 in Capital Medical University,Beijing Friendship Hospital between January 2012 to July 2018,the average age was 70.7 years,and the age range was 63-77 years.Among them,137 patients with benign diseases,30 patients with clinically insignificant prostate cancer (CIPCa),and 51 patients with CSPCa.Models were established based on clinical variables.The measurement data were expressed as the median (interquartile range) [M(P25,P75)],and the rank sum test was used for comparison between groups;the Chi-square test was used for comparison between the count data groups.The decision curve was used to determine the clinical net benefit unilateral factors generated by the application of the model,univariate and multivariate logistic regression analysis to determine the predictors of positive outcomes.The diagnostic performance of the predictive model was evaluated by the area under the curve (AUC) of receiver operating curve,which was used to assess the overestimation or underestimation of the model,and the decision curve was used to determine the clinical net gain from the application of the model.Results Detection of prostate caner (PCa) and CSPCa in the PI-RADs v2 cohort were 37.2％ (81/218) and 23.4％ (51/218).The median prostate specific antigen of CSPCa patients was 12.1 ng/ml,which was higher than CIPCa (9.5 ng/ml) and benign (10.5 ng/ml) patients.The median prostate volume of CSPCa patients was 41.2 ml,lower than CIPCa (45.8 ml) and benign (57.3 ml) patients.The median prostate special antigen density (PSAD) was 0.28 ng/ml2,higher than CIPCa (0.20 ng/ml2) and benign (0.15 ng/ml2) patients.The predictive power of the developed model,based on age,PSAD,lesion region and ADC value,showed a higher AUC than that of parameters alone.Internally validated calibration curves showed that the nomogram might overestimate the risk of PCa when the threshold was above 35％.As for CSPCa,the predicted risk was closer to actual probability wben the threshold was above 60％.Decision curves showed that a better net benefit was met when the model was used to guide clinical practice.Conclusions The models based on age,PSAD,lesion region and ADC value showed internally validated high predictive value for both PCa and CSPCa.It could be used to improve the detection rate of CSPCa and avoid unnecessary biopsy.
ABSTRACT
OBJECTIVE: To retrospectively determine whether the use of the Prostate Imaging Reporting and Data System (PI-RADS) version 2 (v2) helps predict long-term outcomes for prostate cancer (PCa) patients following radical prostatectomy (RP). MATERIALS AND METHODS: A total of 166 patients with localized PCa evaluated with multiparametric magnetic resonance imaging (mpMRI) at 3T before RP were enrolled. Three groups were created based on PI-RADS v2 score used to predict clinical outcomes: group A, ≥ 3; group B, ≥ 4; group C, 5. We calculated biochemical recurrence-free survival (RFS) and progression-free survival (PFS). Cox proportion hazards models were used to identify variables predictive of biochemical recurrence and disease progression. RESULTS: During a median follow-up of 9.1 years, biochemical recurrence occurred in 67 patients (40.4%) and disease progression occurred in 55 patients (33.1%). In all groups, 10-year RFS and 10-year PFS were significantly lower for PI-RADS scores ≥ 3, ≥ 4 and 5 than for score < 3, < 4 and < 5 (p <0.05), respectively. In multivariate analysis, PI-RADS score ≥ 3 and score 5 were significant independent risk marker for biochemical recurrence (hazard ratio [HR] = 5.58, p = 0.018; HR = 1.75, p = 0.033) and disease progression (HR = 3.99, p = 0.047; HR = 2.31, p = 0.040). Moderate inter-observer agreement was seen for PI-RADS scoring. CONCLUSION: PI-RADS v2 may be used to predict long-term outcomes following RP in PCa.
Subject(s)
Humans , Male , Disease Progression , Disease-Free Survival , Follow-Up Studies , Information Systems , Magnetic Resonance Imaging , Multivariate Analysis , Passive Cutaneous Anaphylaxis , Prognosis , Proportional Hazards Models , Prostate , Prostatectomy , Prostatic Neoplasms , Recurrence , Retrospective StudiesABSTRACT
Objective To compare the diagnostic accuracy of clinically significant prostate cancer by general radiologist and uroradiology specialist based on the Prostate Imaging Reporting and Data System (PI-RADS).Methods A total of 45 men from Beijing United Family Hospital and Clinics undergoing prostate mpMRI examination and subsequent MRI-targeted biopsy were included in the study.The age of patients was (60.0 ± 8.0) years,the median PSA level was 7.2 ng/ml (1.2-95.8 ng/ml) and the median prostate volume was 45.0 ml (18.3-127.0 ml).The general radiologists from Beijing United Family Hospital and Clinics made the diagnosis according to PI-RADS 2.0.One uroradiology specialist from Beijing Anzhen hospital reviewed all the mpMRIs retrospectively and marked new PI-RADS score based on PI-RADS 2.0.The PI-RADS ≥ 3 lesion was recognized as suspicious of clinically significant prostate cancer.The distribution of PI-RADS score from different doctors and the diagnostic accuracy of clinically significant prostate cancer was compared.Results All the 45 patients underwent MRI-targeted cognitive biopsy and 14 cases of prostate cancer were detected,including 9 cases of clinically significant prostate cancer.There was no significant difference in the distribution of PI-RADS by general radiologist and uroradiology specialist (P =0.064).82.8％ (37/45) and 37.8％ (17/45) patients were diagnosed with PI-RADS ≥ 3 by general radiologist and uroradiology specialist respectively.The interobserver agreement was only 17.8％ (8/45).The positive predictive value of PI-RADS≥3 was 35.1％ (13/37) and 76.5％ (13/17) for prostate cancer by general radiologist and uroradiology specialist respectively,and for clinically significant prostate cancer,the positive predictive value of PI-RADS ≥ 3 was 21.6％ (8/37) and 52.9％ (9/17) respectively.Conclusions Uroradiology specialist achieved significantly superior in predictive value of PI-RADS for clinically significant prostate cancer compared with general radiologist.In the experienced centers,MRI-targeted biopsy could be performed only on high PI-RADS score lesions,thus to reduce unnecessary biopsies and to avoid over diagnosis and over treatment of prostate cancer.
ABSTRACT
PURPOSE: The aim of this study is to confirm the detection rate of transperineal biopsy after multiparametric magnetic resonance imaging (mpMRI) and compared it to that of transrectal biopsy. We also examined the role of mpMRI and the rate of complications for each method. MATERIALS AND METHODS: In a retrospective study, we analyzed 147 patients who underwent mpMRI before prostate biopsy because of elevated serum prostate-specific antigen and/or abnormal digital rectal examination findings at Korea University Hospital, Seoul, Korea from March 2017 to April 2018. Regions on the mpMRI that were suggestive of prostate cancer were categorized according to the Prostate Imaging–Reporting and Data System (PI-RADS v2). For transperineal biopsy, a 20-core saturation biopsy was performed by MRI-TRUS cognitive or fusion techniques and a 12-core biopsy was performed in transrectal biopsy. RESULTS: Sixty-three and 84 patients were enrolled in transperineal group and transrectal group, respectively. The overall detection rate of prostate cancer in transperineal group was 27% higher than that in transrectal group. Classification according to PI-RADS score revealed a significant increase in detection rate in all patients, as the PI-RADS score increased. Frequency of complications using the Clavien-Dindo classifications revealed no significant differences in the total complications rate, but two patients in transrectal group received intensive care unit care due to urosepsis. CONCLUSIONS: Our results confirmed that transperineal biopsy is superior to transrectal biopsy for the detection of prostate cancer. From the complication point of view, this study confirmed that there were fewer severe complications in transperineal biopsy.
Subject(s)
Humans , Biopsy , Classification , Digital Rectal Examination , Information Systems , Intensive Care Units , Korea , Magnetic Resonance Imaging , Methods , Prostate , Prostate-Specific Antigen , Prostatic Neoplasms , Retrospective Studies , SeoulABSTRACT
The main purpose of Prostate Imaging-Reporting and Data System Version 2 (PI-RADSv2) is to effectively detect clinically significant prostate cancers (csPCa) using multiparametric magnetic resonance imaging. Since the first introduction of PI-RADSv2, researchers have validated its diagnostic performance in identifying csPCa, and these promising data have influenced biopsy and treatment schemes. However, in this article, we focused on the potential of PI-RADSv2 in relation to various aspects of PCa such as Gleason score, tumor volume, extraprostatic extension, lymph node metastasis, and postoperative biochemical recurrence, beyond prostate cancer detection.
Subject(s)
Biopsy , Information Systems , Lymph Nodes , Magnetic Resonance Imaging , Neoplasm Grading , Neoplasm Metastasis , Passive Cutaneous Anaphylaxis , Prognosis , Prostate , Prostatic Neoplasms , Recurrence , Tumor BurdenABSTRACT
OBJECTIVE: This study's purposes were to determine the yield of repeat direct in-bore magnetic resonance-guided prostate biopsy (MRGB) (MRGB-2) after the first one was found to be negative (MRGB-1), to correlate with clinical parameters, and to present the subgroup analyses of patients with positive repeat biopsies, despite having a negative initial biopsies. MATERIALS AND METHODS: We retrospectively included patients with MRGB-2 after a negative MRGB-1 both between January 2006 and August 2016. This study included 62 patients (median age, 63 years; interquartile range [IQR], 58–66 years) with 75 sampled lesions during MRGB-2 left for analysis, and 63 lesions were resampled and 12 new lesions were sampled. Included patients had a prostate specific antigen (PSA) at MRGB-1 of 13 ng/mL (IQR, 5.8–20.0) and a PSA at MRGB-2 of 15 ng/mL (IQR, 9.0–22.5). All anonymized magnetic resonance imaging (MRI) data were retrospectively reassessed according to Prostate Imaging-Reporting and Data System version 2 by two radiologists. Images of MRGB were compared to determine whether the same prostate lesion was biopsied during MRGB-1 and MRGB-2. Descriptive statistics were utilized to determine the yield of clinically significant prostate cancer (csPCa) at MRGB-2. Gleason score of ≥ 3 + 4 was considered csPCa. RESULTS: In 16/75 (21%) lesions csPCa was detected during MRGB-2. Of 63 resampled lesions, 13 (21%) harbored csPCa at MRGB-2. In two patients, csPCa was detected on repeat biopsy, while the volume of the lesion decreased between MRGB-1 and MRGB-2. CONCLUSION: Patients could benefit from repeat biopsy after negative initial MRGB, especially in the case of increasing PSA values and persisting PCa suspicion in MRI. Further research is needed to establish predictors for positive repeat targeted biopsies.
Subject(s)
Humans , Male , Anonyms and Pseudonyms , Biopsy , Information Systems , Magnetic Resonance Imaging , Neoplasm Grading , Passive Cutaneous Anaphylaxis , Prostate , Prostate-Specific Antigen , Prostatic Neoplasms , Retrospective StudiesABSTRACT
Objective To investigate the diagnostic value of multiparametric MRI in early prostate cancer(PCa) based on PI-RADS version 2.Methods 27 surgically-proved early PCa patients were collected in this retrospective study.T2WI,DWI and DCE were evaluated by two blinded radiologists.By 12 sub-region classification method the possibility of the presence of cancer at each sub-region was scored according to the PI-RADS V2.The receiver operating characteristic (ROC) curve was used to analyze the diagnosic efficacy of the following 4 protocols:T2WI alone(protocol 1),T2WI+DWI(protocol 2),T2WI+DCE(protocol 3),T2WI+DWI+DCE(protocol 4).The sensitivity,specificity and accuracy for each protocol were calculated.The average scores of cancerous sub-regions and non-cancerous sub-regions were calculated and the independent sample t test was used to compare the four protocols.Results 324 sub-regions were analyzed in 27 early PCa patients and then divided into 119 cancerous sub-regions and 205 non-cancerous sub-regions,including 64 peripheral zone cancerous sub-regions and transition zone cancerous sub-regions.In protocol 1-4, the average scores of cancerous sub-regions in orderwere 3.13±1.19,3.27±1.15,3.28±1.23, 3.33±1.16,respectively.Non-cancerous sub-regions's scores in order were 1.98±0.90,1.91±0.91, 2.03±0.99,1.94±0.96 respectively and there were significant differences among each protocol (P0.05).In four protocols, the sensitivity in order were 45.40%, 56.30%, 59.70%, 61.34%, while the specificity in order were 95.10%, 96.10%, 89.80%, 96.60%, and the accuracy in order were 76.85%, 81.48%, 78.70%, 83.65%.Conclusion Multiparametric MRI can improve the diagnostic accuracy for the detection of early PCa, and T2WI+DWI+DCE is with the highest value.The PI-RADS V2 system is a better semi quantitative method for evaluation of early PCa.
ABSTRACT
Prostate cancer is the most common cancer among men aged 50 years and older in developed countries and the third leading cause of cancer-related death in men. Multiparametric prostate MR imaging is currently the most accurate imaging modality to detect, localize, and stage prostate cancer. The role of multi-parametric MR imaging in the detection of clinically significant prostate cancer are discussed. In addition, insights are provided in imaging techniques, protocol, and interpretation.